Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Propanc Biopharma Inc (PPCB)

Propanc Biopharma Inc (PPCB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Propanc Biopharma Advances POP1 Drug Discovery Program

Propanc Biopharma, Inc. (OTC: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today...

PPCB : 0.2700 (+4.65%)
Propanc Biopharma Provides Shareholder Update and Forecast for 2020

Propanc Biopharma, Inc. (OTC: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today...

PPCB : 0.2700 (+4.65%)
Propanc Biopharma Illustrates Novel Mode of Action of PRP, Suppressing EMT Pathways and Metastasis in Cancer Patients

Propanc Biopharma, Inc. (OTC: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today...

PPCB : 0.2700 (+4.65%)
Propanc Biopharma Receives Granted US Patent Covering Additional Composition Claims for PRP

Propanc Biopharma, Inc. (OTC: PPCB) ("Propanc"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today that it has received...

PPCB : 0.2700 (+4.65%)
CORRECTING and REPLACING Propanc Biopharma Publishes Key Data in Peer Reviewed Journal Confirming Anti-Cancer Stem Cell Effects of Proenzymes

First paragraph, first sentence of release should read: Propanc Biopharma, Inc. (OTC: PPCB) ("Propanc"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring...

PPCBD : 1.9900 (-9.55%)
PPCB : 0.2700 (+4.65%)
Propanc Biopharma Publishes Key Data in Peer Reviewed Journal Confirming Anti-Cancer Stem Cell Effects of Proenzymes

Propanc Biopharma, Inc. (OTC: PPCBD) ("Propanc"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the company's...

PPCB : 0.2700 (+4.65%)
PPCBD : 1.9900 (-9.55%)
Propanc Biopharma Completes Development of Bio-analytical Assay Method to Quantify PRP's Active Ingredients in Preparation for First-In-Human Study

Propanc Biopharma, Inc. (OTC: PPCB) ("Propanc"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today it has developed...

PPCB : 0.2700 (+4.65%)
Propanc Biopharma Provides Update on Preparation of PRP for Clinical Trial Application Submission and Recently Completed Reverse Stock Split

Propanc Biopharma, Inc. (OTC: PPCBD) ("Propanc"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today an update on...

PPCB : 0.2700 (+4.65%)
PPCBD : 1.9900 (-9.55%)
Propanc Biopharma's Intellectual Property Portfolio Undergoes Rapid Growth

Propanc Biopharma, Inc. (OTC: PPCBD) ("Propanc"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today that Propanc's...

PPCB : 0.2700 (+4.65%)
PPCBD : 1.9900 (-9.55%)
Propanc Biopharma Appoints Carlo Campiciano as Chief Financial Officer

Propanc Biopharma, Inc. (OTC: PPCB) ("Propanc", the "Company", "we", "our", or "us"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer,...

PPCB : 0.2700 (+4.65%)
Propanc Biopharma Appoints Dr. Ralf Brandt to its Scientific Advisory Board

Propanc Biopharma, Inc. (OTCQB: PPCB) ("Propanc"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced...

CGIX : 5.51 (-28.44%)
PPCB : 0.2700 (+4.65%)
Propanc Biopharma Initiates Development of Bio-Analytical Assay in Preparation for Human Trials

Propanc Biopharma, Inc. (OTCQB: PPCB) ("Propanc"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today that it has...

PPCB : 0.2700 (+4.65%)
Propanc Biopharma Initiates Development of Bio-Analytical Assay in Preparation for Human Trials

MELBOURNE, Australia , March 25, 2019 /PRNewswire/ --  Propanc Biopharma, Inc. (OTCQB: PPCB) ("Propanc"), a biopharmaceutical company developing new cancer treatments for patients suffering...

PPCB : 0.2700 (+4.65%)
OTC Markets Group Announces Gold Sponsorship of 31st Annual ROTH Conference

OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today unveiled the list of OTCQX® Best Market and OTCQB® Venture Market company presentations...

ACRGF : 5.2400 (+1.55%)
ALEAF : 0.4901 (-1.98%)
ARREF : 0.3743 (-1.24%)
CWBHF : 8.8200 (-1.29%)
CORVF : 1.4948 (+6.77%)
CRLBF : 4.6800 (+2.72%)
DYAI : 5.95 (-0.83%)
ELLXF : 0.6500 (-1.66%)
EMHTF : 0.2500 (-2.19%)
GLDLF : 0.9213 (+4.69%)
GTBIF : 8.0840 (-1.11%)
GRWG : 3.92 (-3.57%)
HEOFF : 0.7807 (+8.85%)
ITHUF : 1.1800 (-4.84%)
IMLFF : 0.1875 (+3.02%)
ISYRF : 1.1800 (-3.27%)
MMNFF : 0.4010 (-4.98%)
MTAFF : 0.9961 (+1.64%)
MJARF : 0.1400 (-3.25%)
NUPMF : 3.6493 (+1.38%)
NLST : 0.3300 (-3.17%)
STLHF : 0.6149 (-14.22%)
TRLFF : 0.1200 (+33.33%)
AITB : 5.24 (+2.34%)
ALYE : 0.8100 (-40.88%)
ARTH : 0.2350 (-4.08%)
ARHH : 1.3900 (+5.30%)
ATEA : 11.9500 (unch)
BICXD : 4.5400 (-9.02%)
BRTI : 0.1150 (-14.81%)
CNBX : 0.1151 (-10.01%)
CLOK : 0.8500 (-10.53%)
CVSI : 0.9500 (-5.00%)
DUOT : 0.4600 (-1.16%)
EVLLF : 1.1198 (+0.89%)
FLUX : 9.0000 (+0.56%)
GBPT : 7.1000 (+56.04%)
GTBP : 0.1250 (+7.76%)
KSHB : 1.6400 (-1.80%)
MRMD : 0.5390 (-9.26%)
MLCPF : 3.5200 (+11.47%)
MRIC : 3.90 (+2.63%)
NMUS : 0.6500 (-9.52%)
NWGI : 0.4650 (+1.09%)
OWCP : 0.0064 (unch)
PPCB : 0.2700 (+4.65%)
QBIO : 1.5000 (+1.35%)
RSSS : 3.2500 (-1.52%)
VTLR : 0.0600 (-4.91%)
WIZD : 0.0800 (+12.68%)
OTCM : 34.5000 (+2.22%)
Propanc Biopharma Receives Notice of Allowance for Additional Claims from Foundation Patent in the U.S.

Propanc Biopharma, Inc. (OTCQB: PPCB) ("Propanc"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today that it has...

PPCB : 0.2700 (+4.65%)
Propanc Biopharma to Present at the 31st Annual ROTH Conference March 17 - 19, 2019

Propanc Biopharma, Inc. (OTCQB:PPCB) ("Propanc"), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced...

PPCB : 0.2700 (+4.65%)
Propanc Biopharma to Present at the 2019 BIO CEO & Investor Conference

Propanc Biopharma, Inc. (OTCQB: PPCB) ("Propanc"), a clinical stage biopharmaceutical company focused on development of new and proprietary treatments for cancer patients suffering...

PPCB : 0.2700 (+4.65%)
Fighting Cancer at the Root: VeraStem and Propanc Biopharma

TORONTO, ON / ACCESSWIRE / January 23, 2019 / The Wealthy Venture Capitalist (or "WVC"), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known...

VSTM : 1.25 (-8.76%)
PPCB : 0.2700 (+4.65%)
BLCM : 0.81 (-2.80%)
CLLS : 14.56 (-0.14%)
INO : 2.33 (-5.67%)
OMED : 0.93 (+4.49%)
BAYN : 0.0147 (unch)
CELG : 108.24 (+0.10%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +0.47 , AIZ +1.31 , SBAC +0.58 , SO +0.07 , WELL +0.28
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar